The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.

PRIORITY PRESS - ASH 2023: Annual Meeting of the American Society of Hematology

“PNH is getting very popular!”: New clinical trial data and management insights from ASH 2023

San Diego, California / December 9–12, 2023

San Diego – Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired disorder of hematopoietic stem cells that leaves red blood cells (RBCs) susceptible to complement-mediated lysis, with clinical manifestations that can...

PRIORITY PRESS - SNO 2023: Annual Meeting of the Society for NeuroOncology

A deep dive into neurofibromatosis type 1: Expert experiences and perspectives from SNO 2023

Vancouver, British Columbia / November 15–19, 2023

Vancouver – The Society for NeuroOncology (SNO) is an international organization that brings together clinicians and researchers with an interest in central nervous system malignancies. Although a large part of its focus is on...

PRIORITY PRESS - SIOP 2023: Annual Meeting of the International Society of Paediatric Oncology

Understanding the burden and management of NF1: Insights from SIOP 2023

Ottawa, Ontario / October 11–14, 2023

Ottawa – The annual conference of the International Society of Paediatric Oncology (Société internationale d’oncologie pédiatrique, SIOP) brought clinicians and researchers from around the world to...

MEDICAL FRONTIERS - 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO)

A New Era Emerges In Melanoma Control, Including Brain Metastases

Chicago, Illinois / June 2-6, 2017

Chicago - A growing proportion of patients with advanced metastatic melanoma are surviving for long periods due largely to two approaches. One involves combining therapies targeted at the BRAF and MEK pathways. The other involves...

PRIORITY PRESS - Lung Cancer Summit 2015

The Right Drug at the Right Time in the Right Patient: Reflex Biomarker Testing in NSCLC Should Become a National Strategy

Toronto, Ontario / October 30, 2015

Toronto - Recent guidelines from the American Society of Clinical Oncologists state that systemic therapy for advanced non-squamous non-small cell lung cancer (NSCLC) should start with knowledge of a patient’s biomarker status...

PHYSICIAN PERSPECTIVE - Viewpoint based on presentations from the European Cancer Congress (ECC)

Neuroendocrine Tumours: Revised Strategies from New Trial Data

Vienna, Austria / September 25-29, 2015

Guest Editor: Simron Singh, MD, MPHStaff Oncologist Assistant Professor, University of TorontoSunnybrook Health Sciences Centre Toronto, Ontario   Introduction NET is a term for a genetically diverse group of solid tumours arising...

PRIORITY PRESS - 39th Annual Congress of the European Society for Medical Oncology (ESMO)

Survival Data Justify Early Use of Androgen Pathway Inhibitor in Metastatic Castration Resistant Prostate Cancer

Madrid, Spain / September 26-30, 2014

Madrid - The final overall survival (OS) results of a phase 3 multicentre trial have confirmed the value of first-line androgen inhibition in metastatic castration resistant prostate cancer (mCRPC). In the study, early use of an androgen...

PRIORITY PRESS - 39th Congress of the European Society for Medical Oncology (ESMO)

Objective Response to a TKI in Metastatic Renal Cell Cancer Is Substantially Improved with Individualized Dose Schedules

Madrid, Spain / September 26-30, 2014

Madrid - Optimal response to a tyrosine kinase inhibitor (TKI) employed first line in metastatic renal cell carcinoma (mRCC) appears to be achieved by individualizing the dose and schedule in order to sustain dose intensity, according to...

PRIORITY PRESS - 39th Congress of the European Society for Medical Oncology (ESMO)

Targeted Therapies Moving into First-Line Therapy Underscore Need for Baseline Molecular Testing of Lung Cancers

Madrid, Spain / September 26-30, 2014

Madrid - Guidelines issued by ESMO just prior to the annual Congress call for routine molecular testing at the time of diagnosis in all patients with non-small cell lung cancer (NSCLC). New phase 3 data on ALK-positive (ALK+) NSCLC...

PAGE 1 OF 23   1 2 3 4 5 6 7 8 9 10 ...